Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Canadian biotech firm Bioniche Life Sciences has had another patent granted on its core technology, Mycobacterial Cell Wall-DNA Complex, providing protection for its use as a means of inducing programmed cell death in prostate cancers.
Subscribe to our email newsletter
The European Patent Organization granted the patent for the Mycobacterial Cell Wall-DNA Complex (MCC), which comprises compositions with antiviral, immune adjuvant, and immune stimulatory activity, as well as chemotherapeutic activity against cancer cells.
A number of compositions are commercialized for use in veterinary applications, and the company is actively developing compositions for use in a number of human applications.
Graeme McRae, president & CEO of Bioniche, said: “The mycobacterial cell wall technology is the core of our product development pipeline. The latest formulation of the technology – MCC – is being targeted for the treatment of bladder cancer initially, with a phase III clinical trial planned in North America and Europe. We have already conducted a phase I clinical study for prostate cancer and plan to initiate further studies once the bladder cancer phase III trial is underway.”